menu search

Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates

Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates
– Top-line data from Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) in NASH expected in third quarter of 2023 – TERN-701 (allosteric BCR-ABL) Phase 1 trial for CML on track to initiate in the U.S. in second half of 2023; enrollment progress update from ongoing China Phase 1 trial expected at the 2023 […] The post Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates appeared first on ForexTV... Read More
Posted: May 15 2023, 12:05
Author Name: forextv
Views: 103185

Search within

Pages Search Results: